Evidence map›Paper›PMID 37808318›Full record

ArticleFrontiers in microbiology2023

Hepatitis C virus alters the morphology and function of peroxisomes.

Esther Martin de Fourchambault, Nathalie Callens, Jean-Michel Saliou, Marie Fourcot, Oceane Delos, Nicolas Barois, Quentin Thorel, Santseharay Ramirez, Jens Bukh, Laurence Cocquerel and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. The peroxisome: an update on mysteries 3.0.Histochemistry and cell biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Esther Martin de FourchambaultUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U 1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Nathalie CallensUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U 1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Jean-Michel SaliouUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UAR CNRS 2014 - US Inserm 41 - PLBS, Lille, France.
Marie FourcotUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UAR CNRS 2014 - US Inserm 41 - PLBS, Lille, France.
Oceane DelosMetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France.
Nicolas BaroisUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U 1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Quentin ThorelUniversité de Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, Lille, France.
Santseharay RamirezFaculty of Health and Medical Sciences, Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital Hvidovre and Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Jens BukhFaculty of Health and Medical Sciences, Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital Hvidovre and Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Laurence CocquerelUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U 1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Justine Bertrand-MichelMetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France.
Guillemette MarotUniversité de Lille, Inria, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, France.
Yasmine SebtiUniversité de Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, Lille, France.
Jean DubuissonUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U 1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Yves RouilléUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U 1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Center for Infection and Immunity of Lille · FRInserm · FRCentre Hospitalier Universitaire de Lille · FRCentre National de la Recherche Scientifique · FRHvidovre Hospital · DKInstitut Pasteur de Lille · FRUniversité de Lille · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversité Toulouse III - Paul Sabatier · FRUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the introduction of effective treatments for hepatitis C in clinics, issues remain regarding the liver disease induced by chronic hepatitis C virus (HCV) infection. HCV is known to disturb the metabolism of infected cells, especially lipid metabolism and redox balance, but the mechanisms leading to HCV-induced pathogenesis are still poorly understood. In an APEX2-based proximity biotinylation screen, we identified ACBD5, a peroxisome membrane protein, as located in the vicinity of HCV replication complexes. Confocal microscopy confirmed the relocation of peroxisomes near HCV replication complexes and indicated that their morphology and number are altered in approximately 30% of infected Huh-7 cells. Peroxisomes are small versatile organelles involved among other functions in lipid metabolism and ROS regulation. To determine their importance in the HCV life cycle, we generated Huh-7 cells devoid of peroxisomes by inactivating the PEX5 and PEX3 genes using CRISPR/Cas9 and found that the absence of peroxisomes had no impact on replication kinetics or infectious titers of HCV strains JFH1 and DBN3a. The impact of HCV on peroxisomal functions was assessed using sub-genomic replicons. An increase of ROS was measured in peroxisomes of replicon-containing cells, correlated with a significant decrease of catalase activity with the DBN3a strain. In contrast, HCV replication had little to no impact on cytoplasmic and mitochondrial ROS, suggesting that the redox balance of peroxisomes is specifically impaired in cells replicating HCV. Our study provides evidence that peroxisome function and morphology are altered in HCV-infected cells.

Indexed as

APEX2CRISPR-Cas9HCV genotypehepatitis C virusperoxisomeproximity biotinylationROS

Identifiers

PMID37808318
PMCPMC10551450
OpenAlexW4386925766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.